Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS
Abstract
Accumulation of insoluble amyloid fibrils is widely studied as a critical factor in the pathology of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. Misfolded Cu, Zn superoxide dismutase (SOD1) was the first protein linked to ALS, and non-native SOD1 trimeric oligomers were recently linked to cytotoxicity, while larger oligomers were protective to cells. The balance between trimers and larger aggregates in the process of SOD1 aggregation is, thus, a critical determinant of potential therapeutic approaches to treat ALS. Yet, it is unknown whether these trimeric oligomers are a necessary intermediate for larger aggregate formation or a distinct off-pathway species competing with fibril formation. Depending on the on- or off-pathway scenario of trimer formation, we expect drastically different therapeutic approaches. Here, we show that the toxic SOD1 trimer is an off-pathway intermediate competing with protective fibril formation. We design mutant SOD1 constructs that remain in a trimeric state (super stable trimers) and show that stabilizing the trimeric SOD1 prevents formation of fibrils in vitro and in a motor neuron like cell model (NSC-34). Using size exclusion chromatography we track the aggregation kinetics of purified SOD1 and show direct competition of trimeric SOD1 with larger oligomer and fibril formation. Finally, we show the trimer is structurally independent of both larger soluble oligomers and insoluble fibrils using circular dichroism spectroscopy and limited proteolysis. Significance StatementProtein aggregation into large insoluble species is a hallmark of many neurodegenerative diseases, but recent evidence suggests that smaller soluble aggregates are responsible for neuronal death. Depending on whether these toxic oligomers appear on- or off-pathway to larger aggregates, which is currently unknown, the strategies for pharmaceutic intervention would be drastically different. Here, we determine that stabilizing the trimeric form of SOD1 reduces larger aggregate formation while increasing toxicity to cells. Trimeric and larger aggregate concentrations have a strong negative correlation over time, and the structure of the trimer is significantly different from larger soluble and insoluble aggregates. Our findings show that formation of trimeric SOD1 is directly competing with that of larger aggregates.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 18
- FWCI
- 2.11
- Field percentile
- top 12%
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Unveiling the double-edged sword: SOD1 trimers possess tissue-selective toxicity and bind septin-7 in motor neuron-like cells
Esther Sue Choi, Brianna Hnath, … Nikolay V. Dokholyan·StructurePeer-reviewed·Aug 28, 2024
- Cryo-EM structure of an amyloid fibril formed by full-length human SOD1 reveals its pathological conformational conversion
L.-Q. Wang, Y. Ma, … Y. Liang·bioRxiv·Dec 7, 2021
- Tryptophan residues in TDP-43 and SOD1 mediate the cross-seeding and toxicity of SOD1
E. Pokrishevsky, M. G. Duval, … N. R. Cashman·bioRxiv·Jul 27, 2020
- Mutant SOD1 expressed by oligodendrocytes aggregates in myelinic nanochannels and accelerates disease progression in familial ALS mice
Alexandra I. Mot, Ying Li, … Klaus‐Armin Nave·bioRxiv·Jun 11, 2026
- A structure-guided antibody detects SOD1 oligomers in diverse ALS genotypes.
Smriti Sangwan, Hannah E. Rieder, … David S Eisenberg·bioRxiv·May 5, 2025
- TNF receptor associated factor 6 interacts with ALS-linked misfolded superoxide dismutase 1 and promotes aggregation
Sabrina Semmler, Myriam Gagné, … Christine Vande Velde·Journal of Biological ChemistryPeer-reviewed·Feb 6, 2020